nimodipine has been researched along with Chronic Fatigue and Immune Dysfunction Syndrome in 1 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chronic fatigue syndrome is a heterogeneous condition with as proves effective treatment." | 2.68 | N of 1 trials. Managing patients with chronic fatigue syndrome: two case reports. ( Wiebe, E, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wiebe, E | 1 |
1 trial available for nimodipine and Chronic Fatigue and Immune Dysfunction Syndrome
| Article | Year |
|---|---|
N of 1 trials. Managing patients with chronic fatigue syndrome: two case reports.
Topics: Adult; Calcium Channel Blockers; Cross-Over Studies; Decision Support Techniques; Double-Blind Metho | 1996 |